Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 04

468P - Impact of low HER2 status on CDK4/6 inhibitor and endocrine therapy in metastatic HR+ breast cancer: A retrospective multicenter study

Date

21 Oct 2023

Session

Poster session 04

Topics

Tumour Site

Breast Cancer

Presenters

Eda Caliskan Yildirim

Citation

Annals of Oncology (2023) 34 (suppl_2): S334-S390. 10.1016/S0923-7534(23)01260-7

Authors

E. Caliskan Yildirim1, E. Atag2, E. Yuzugullu3, O.U. Unal4, A. Celebi5, M. Keser6, M. Uzun7, M. Keskinkilic8, E. Tanrikulu Simsek9, M. Sari10, T. Yavuzsen8

Author affiliations

  • 1 Medical Oncology Dept., Dokuz Eylul University - Faculty of Medicine, 35210 - Izmir/TR
  • 2 Medical Oncology Dept., Dokuz Eylul University - Faculty of Medicine, 35340 - Izmir/TR
  • 3 Medical Oncology, Haydarpasa Numune Education and Research Hospital, 34668 - Istanbul/TR
  • 4 Medical Oncology, Tepecik Education and Research Hospital, 35180 - Izmir/TR
  • 5 Medical Oncology Dept., Marmara University Pendik Training and Research State Hospital, 34899 - Istanbul/TR
  • 6 Medical Oncology Department, Tepecik Training and Research Hospital, 35020 - Izmir/TR
  • 7 Medical Oncology Dept., Dokuz Eylul University - Faculty of Medicine, Izmir/TR
  • 8 Medical Oncology Dept., Dokuz Eylul University School of Medicine, 35340 - Izmir/TR
  • 9 Medical Oncology Dept., Haydarpasa Numune Education and Research Hospital, İstanbul/TR
  • 10 Medical Oncology Department, Marmara University Pendik Training and Research State Hospital, 34093 - Istanbul/TR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 468P

Background

CDK4/6 inhibitors combined with endocrine therapy have revolutionized the treatment of metastatic HR+ breast cancer. However, the influence of low HER2 expression on treatment response and progression-free survival (PFS) remains unclear.

Methods

We conducted a multicenter retrospective study including 204 HR+ breast cancer patients who received a combination of CDK4/6 inhibitor and endocrine therapy. Among them, 138 (68%) patients exhibited HER2-zero disease, while 66 (32%) patients had HER2-low disease. We analyzed treatment-related characteristics and clinical outcomes, with a median follow-up of 22 months.

Results

In the HER2-low group, the objective response rate (ORR) was 72.7%, compared to 66.6% in the HER2-zero group (p=0.54). Median PFS did not significantly differ between the HER2-low and HER2-zero groups (19 months vs. 18 months, p=0.89). Notably, a trend towards longer PFS was observed in the HER2-low group for first-line treatment (24 months progression-free survival rate: 63% vs. 49%). For recurrent disease, the median PFS was 25 months in the HER2-low group and 12 months in the HER2-zero group (p=0.08), while in de novo metastatic disease, the median PFS was 18 months in the HER2-low group and 27 months in the HER2-zero group (p=0.16). Independent variables affecting PFS were identified as the order of CDK4/6 inhibitor use and the presence of visceral metastasis.

Conclusions

Low HER2 expression did not significantly impact treatment response or PFS in HR+ breast cancer patients treated with a CDK4/6 inhibitor and endocrine therapy. Because of the conflicting results in the literature, further prospective studies are needed to evaluate the clinical significance of HER2 expression in HR+ breast cancer.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.